Top 5 Income Companies To Own For 2014

Popular Posts: 5 REIT ETFs to Buy Now for Big Income3 Stocks to Power Your Portfolio With Canadian Oil SandsGo Sand-Combing for Big Dividends & Returns Recent Posts: Take Your Profits Now: 5 Energy Stocks To Trim in 2014 The 4 Hottest Solar Stocks of 2013 3 Stocks Hitting Gold in the Digital Oilfield View All Posts

Wall Street is full old-timey investment sayings. One of the best adages goes ��ulls make money, Bears make money, but Pigs get slaughtered.��/p>

5 Best US Stocks To Own Right Now: (NWBO)

Northwest Biotherapeutics, Inc., a development stage biotechnology company, engages in the discovery, development, and commercialization of immunotherapy products that generate and enhance immune system responses to treat cancer in the United States. Its technology platforms comprise dendritic cell-based cancer vaccines (DCVax) and monoclonal antibodies for cancer therapeutics. The company?s product candidates include DCVax-Prostate for the treatment of non-metastatic hormone independent prostate cancer, which cleared Phase III clinical trial; DCVax-Brain that is in Phase II clinical trial for the treatment of glioblastoma multiforme; and DCVax-LB, which cleared Phase I clinical trial for the treatment of non-small cell lung cancer. Its product candidates also comprise DCVax-Direct that cleared Phase I clinical trial for the treatment of ovarian, head, and neck cancer; and DCVax-L, which completed Phase I/II clinical trials for the treatment of resectable solid tumors. In addition, the company develops CXCR4 antibodies, which are involved in various phases of disease progression, including proliferation of the primary tumor, migration of cancer cells out of the primary tumor, and establishment of distant metastatic sites for the treatment of non-small cell lung cancer, breast cancer, glioblastoma multiforme, colon cancer, melanoma, prostate, pancreatic, kidney, ovarian, and certain blood cancers. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.

Advisors' Opinion:

• [By Smith On Stocks]

  Using my assumptions, the common of Agenus might be worth about $7.00 per share in early 2014 based on the royalties from the Glaxo vaccines and the net operating loss carry forward even if every other asset in the company were valued at zero. However, there may be substantial value in Agenus' internal vaccine programs in recurrent and newly diagnosed glioblastoma and the genital herpes vaccine. Based on a comparison to peer companies like Northwest Biotherapeutics (NWBO) and ImmunoCellular Therapeutics (IMUC), I believe that the internal programs at Agenus currently may be worth $150 million or $4.45 per share. Adding this to the value of the MAGE A-3 vaccine could produce a stock price of $11.00 in early 2014.

Top 5 Income Companies To Own For 2014: Hillshire Brands Co (HSH)

The Hillshire Brands Company, incorporated on September 4, 1941, is a manufacturer and marketer of food products. The Company�� portfolio includes brands, such as Jimmy Dean, Ball Park, Hillshire Farm, State Fair, Sara Lee frozen bakery and Chef Pierre pies, as well as artisanal brands Aidells and Gallo Salame. The Company operates in two segments: Retail and Foodservice/Other. Retail sells a variety of packaged meat and frozen bakery products to retail customers in North America. Foodservice/other sells a variety of meat and bakery products to foodservice customers in North America. On February 4, 2013, the Company completed the sale of its Australian bakery business.

Retail

Products in the retail segments include hot dogs and corn dogs, breakfast sausages, breakfast convenience items, including breakfast sandwiches and bowls, dinner sausages, deli and luncheon meats and cooked hams, as well as frozen pies, cakes, cheesecakes and other desserts. The Company�� brands include Jimmy Dean, Ball Park, Hillshire Farm, State Fair and Sara Lee, as well as artisanal brands Aidells and Gallo Salame. The sales of the Retail business are generated in the United States Sales are made in the retail channel to supermarkets, warehouse clubs and national chains. Retail�� business accounted for 74% of the Company�� sales during the fiscal year ended June 29, 2013 (fiscal 2013).

Foodservice/Other

Products in the foodservice/other segment include hot dogs and corn dogs, breakfast sausages and sandwiches, dinner sausages, deli and luncheon meats, ham, beef and turkey, as well as a variety of bakery products, including pastries, muffins, frozen pies, cakes and cheesecakes. Sales are made in the foodservice channel to distributors, restaurants, hospitals and other large institutions. Foodservice/Other�� business accounted for 26% of the Company�� sales in fiscal 2013.

Advisors' Opinion:

• [By Jack Kramer and Nick Martell]

  3. Tyson Foods finally buys Hillshire Brands in big meat merger
  How much does a Ball Park frank cost? It doesn't matter any more for Tyson Foods (NYSE: TSN  ) , because it's buying the hot dog and Jimmy Dean sausage maker, also known as Hillshire Brands (NYSE: HSH  ) . Both companies announced the mergers on their websites Monday, but the stocks moved in opposite directions.

• [By Matt Thalman]

  And finally, Hormel. The stock fell after the CEO of Hillshire Brands (NYSE: HSH  ) said that his company will look to make some acquisitions in the coming year and focus more on chicken products as consumers begin to demand healthier options. It is clear that the competition will continue to intensify for Hormel in the coming months and years and, as Hillshire is still a smaller company, it could change very quickly if the acquisition-happy CEO goes on a shopping spree. With many of these food brands, it is all about shelf space and location within a store and, more times than not, the bigger the player, the better the location. Hormel investors shouldn't be overly concerned today, but need to watch how things play out in the future. �

• [By Jeremy Bowman]

  Elsewhere, Hillshire Brands� (NYSE: HSH  ) �jumped 5% as Tyson Foods� (NYSE: TSN  ) �appears to have won its bidding war with Pilgrim's Pride�for the parent of Jimmy Dean sausages, as Pilgrim's Pride withdrew its proposal following Tyson's latest offer. The nation's No. 1 poultry producer said it will pay $7.7 billion for Hillshire, or $63 a share. Hillshire has not formally accepted the bid, but the acquisition seems inevitable given that Tyson is the only remaining suitor. Notably, Tyson shares fell 6.5%, a sign that investors believe the poultry-maker is overpaying for the parent of Ball Park franks. Hillshire shares, meanwhile, have gained nearly 70% since offering to buy Pinnacle Foods, which sparked the bidding war between Pilgrim's and Tyson to acquire it.

• [By Jake L'Ecuyer]

  Top Headline
  Hillshire Brands Co (NYSE: HSH) announced its plans to buy Pinnacle Foods (NYSE: PF) for around $6.6 billion including debt. Hillshire will offer $18.00 in cash and 0.50 shares of its common stock for each Pinnacle share.

Top 5 Income Companies To Own For 2014: Anglo American PLC (AAUKY.PK)

Anglo American plc (Anglo American), incorporated on May 14, 1998, is a mining company. The Company�� portfolio include Bulk commodities which consists of iron and manganese, metallurgical coal and thermal; base metals, which consists of copper, nickel and niobium; Precious metals and minerals, which include platinum and diamonds and Other Mining and Industrial. The Company operates in Africa, Brazil, Chile, North and South America, Australia, China, India, Japan, other Asia and Europe. In November 2013, Anglo American PLC announced the completion of its sale of the Amapa iron ore operation in Brazil (Amapa) to Zamin Ferrous Ltd. In January 2014, Anglo American completed the acquisition of Mineral Technology Exploration Production SA (MINTEP) and Societe Miniere d'Alumine SA.

Iron and Manganese

The Company�� Iron Ore portfolio consist a 69.7% holding in Kumba Iron Ore Limited (Kumba), a supplier of seaborne iron ore, and Iron Ore Brazil�� 100% interest in Anglo Ferrous Minas-Rio, a 49% shareholding in LLX Minas-Rio, which owns the port of Acu, and a 70% interest in the Amapa iron ore system. During the year ended December 31, 2012, Kumba operated three mines: Sishen Mine in the Northern Cape, which produced 33.7 million tons (MT) of iron ore, Thabazimbi Mine in Limpopo, with an output of 0.8 MT and Kolomela mine, also in the Northern Cape and produced 1.5 MT. During 2011, Kumba exported more than 85% of its total iron ore sales volumes of 44.4 million tons, with 69% of these exports destined for the People�� Republic of China and the remainder to Europe, Japan, South Korea and the Middle East. Its Minas-Rio iron ore project is located in the states of Minas Gerais and Rio de Janeiro.

The Company�� Manganese interests consist of a 40% holding in Samancor Holdings, which owns Hotazel Manganese Mines and Metalloys, both in South Africa, and a 40% holding in each of the Australian-based operations Groote Eylandt Mining Company (GEMCO) and Tasmanian Electro ! Metallurgical Company (TEMCO), with BHP Billiton owning 60% and having management control. It is producer of seaborne manganese ore and is top three global producers of manganese alloy. Its operations produce a combination of ores, alloys and metal from sites in South Africa and Australia.

Metallurgical Coal

The Company�� coal operations in Australia are based on the east coast, from where Metallurgical Coal serves a range of customers throughout Asia and the Indian subcontinent, and Europe and South America. Its metallurgical coal operation in Canada, Peace River Coal, mainly serves customers in Europe, Japan and South America. Metallurgical Coal operated six mines, one wholly owned and five in which it has a controlling interest. Five of the mines are located in Queensland�� Bowen Basin: Moranbah North (metallurgical coal), Capcoal (metallurgical and thermal coal), Foxleigh (metallurgical coal), Dawson (metallurgical and thermal coal) and Callide (thermal coal). Drayton mine (thermal coal) is in the Hunter Valley in New South Wales. Moranbah North is an underground longwall mining operation with a mining lease covering 100 square kilometers.

Capcoal operates two longwall underground mines and an open cut mine. Together, they produce around 5.0 MT annually of hard coking coal, pulverised coal injection (PCI) and thermal coal. Capcoal also supplies methane-rich seam gas to Energy Developments Limited�� power station. Foxleigh is an open cut operation with an annual output exceeding 1.4 million tons of PCI coal. During 2012, Dawson, which is an open cut operation, produced 4.6 MT total of coking and thermal coal. During 2012, Capcoal operates two underground mines and an open cut mine. Together, they produced around 6.0 Mt of hard coking, pulverised coal injection (PCI) and thermal coals. During 2012, Foxleigh is an open cut operation which produced 1.9 Mt of high quality PCI coal.

Thermal Coal

Thermal Coal operates in South Africa a! nd and is! a joint partner in Cerrejon, Colombia. In South Africa, Thermal Coal wholly owns and operates nine mines and has a 50% interest in the Mafube colliery and Phola washing plant. During 2012, six of the mines supplied 23 million tons per annum of thermal coal to both export and local markets. New Vaal, New Denmark and Kriel collieries are domestic product operations supplying 29 million tons per annum of thermal coal to Eskom, the state-owned power utility. During 2012, Isibonelo mine produced five million tons per annum of thermal coal for Sasol Synthetic Fuels, the coal to liquids producer, under a 20 year supply contract. Thermal Coal�� South African operations route all export thermal coal through the Richards Bay Coal Terminal (RBCT), in which it has a 24.2% shareholding, to customers throughout the Med-Atlantic and Asia-Pacific regions. Within South Africa, 62% of total sales tons are made to the Eskom power utility.

Copper

The Company has interests in six copper operations in Chile. The wholly owned operations consists of the Mantos Blancos and Mantoverde mines, and it hold a 50.1% interest in Anglo American Sur (AA Sur), which includes the Los Bronces and El Soldado mines and the Chagres smelter. It has a 44% interest in the Collahuasi mine. The mines also produce associated by-products, such as molybdenum and silver. In addition, it has interests in Quellaveco and Michiquillay projects in Peru and a 50% interest in the Pebble project in Alaska.

Nickel

Nickel has three ferronickel operations: Codemin and Barro Alto in Brazil and Loma de Niquel in Venezuela. Within the

business unit�� portfolio there are also two projects, Jacare and Morro Sem Bone, both in Brazil, and exploration projects in Finland, Canada and Australia.

Platinum

The Company�� Platinum business, based in South Africa, is the producer of platinum. Platinum mines, processes and refines the entire range of platinum group metals (PGMs): platin! um, palla! dium, rhodium, ruthenium, iridium and osmium. Base metals such as nickel, copper and cobalt sulphate are secondary products and are contributors to earnings. Platinum�� operations exploit reserve of PGMs, known as the Bushveld Complex, which contains PGMbearing Merensky, UG2 and Platreef ores. During the year ended December 31, 2012, Platinum wholly owns 10 mining operations in production, a tailings re-treatment facility, three smelters, a base metals refinery and a precious metals refinery. Concentrating, smelting and refining of the output are undertaken at Rustenburg Platinum Mines��(RPM) metallurgical facilities. During 2012, Platinum�� 100% owned mining operations consists of the five mines at Rustenburg Section: Khomanani, Bathopele, Siphumelele, Thembelani and Khuseleka; Amandelbult Section�� two mines, Tumela and Dishaba, as well as Mogalakwena and Twickenham mines. Union Mine is 85% held with a black economic empowerment (BEE) partner, the Bakgatla-Ba-Kgafela traditional community, holding the remainder. The Unki mine in Zimbabwe is wholly owned.

Diamonds

The Company�� diamond interests are represented by its 40% holding in De Beers. The other shareholders in De Beers are Central Holdings Ltd, which owns 40%, and the Government of the Republic of Botswana (GRB) with 15%. De Beers is a diamond company producing diamonds from its mines in Botswana, Canada, Namibia and South Africa. As of December 31, 2012, De Beers held a 50% interest in Debswana Diamond Company and in Namdeb Diamond Corporation. In addition, De Beers has a 74% holding in South African based De Beers Mines Limited. De%Beers owns 100% of De%Beers Canada. De%Beers owns 100% of The Diamond Trading Company (DTC). De Beers, through Element Six Technologies, is a supplier of industrial supermaterials. Element Six operates internationally, with 10 manufacturing sites globally and a global sales network.

Advisors' Opinion:

• [By Ben Kramer-Miller]

  The Pebble Project is an enormous potential mine in Alaska containing mostly copper, and some gold and molybdenum. The project is owned by the Pebble Partnership, of which Northern Dynasty Minerals owns half, while Anglo American (AAUKY.PK) owns the other half.

Top 5 Income Companies To Own For 2014: PulteGroup Inc.(PHM)

PulteGroup, Inc., through its subsidiaries, engages in homebuilding and financial services businesses primarily in the United States. The company?s homebuilding business includes the acquisition and development of land primarily for residential purposes within the United States; and the construction of housing on such lands. It offers various home designs, including single-family detached, townhouses, condominiums, and duplexes under the Pulte Homes, Del Webb, and Centex brand names. As of December 31, 2011, its homebuilding operations offered homes for sale in approximately 700 communities. The company?s financial services business consists of mortgage banking and title operations. It arranges financing through the origination of mortgage loans for its homebuyers; sells such loans and related servicing rights; and provides title insurance policies as an agent, and examination and closing services to its home buyers. The company was formerly known as Pulte Homes, Inc. an d changed its name to PulteGroup, Inc. in March 2010. PulteGroup, Inc. was founded in 1956 and is headquartered in Bloomfield Hills, Michigan.

Advisors' Opinion:

• [By Holly LaFon]

  We believe that a significant reason these companies were spun-off was to unlock the inherent value that was buried underneath poor investment sentiment and extreme uncertainty with respect to housing. The degree of undervaluation and negativity prompted us to take a closer look at the industry as a whole and ascertain exactly what was occurring. Was there something more going on here? Were there any catalysts to spark a recovery, and if so, who would benefit? We may have been drawn to housing through our focus on spin-offs, but recognizing the turnaround/industry restructuring that was taking place led us to invest directly in homebuilders such as Toll Brothers (TOL) and Pulte Group (PHM), which provided the greatest contribution to the Funds' performance.

Top Energy Companies For 2014

SAN FRANCISCO (MarketWatch) ��Energy stocks inched higher Monday, losing steam on the heels of a record close for the Dow Jones Industrial Average in the previous session.

But Transocean Ltd. (RIG) �climbed, leading energy stocks on the S&P 500 Index with a 3.7% gain, after the offshore driller announced two measures in a deal with activist investor Carl Icahn.

The company said Monday it will raise its dividend 34% to $3 from $2.24 a share at its May annual meeting. If approved by the board, the dividend increase will be a 5.6% yield based on Friday�� closing.

5 Best Media Stocks To Own Right Now: Vestas Wind Systems A/S (VWS)

Vestas Wind Systems A/S is a Denmark-based company active within the wind power industry. The Company operates within four business areas: Finance, Sales, Manufacturing & Global Sourcing, and Technology & Service Solutions. The Finance business area focuses on business support services. The Sales business area is divided into six geographical units: Americas, Asia Pacific & China, Central Europe, Mediterranean, Northern Europe and Offshore. The Manufacturing & Global Sourcing business area is engaged in the manufacturing of assembly, blades, components, controls and generators. The Technology & Service Solutions business area is responsible for the engineering solutions, platform and product management, as well as service engineering, among others. As of December 31, 2012, the Company operated globally through a network of subsidiaries located in Denmark, Germany, Italy, China, the United States, Spain, Estonia, Sweden and Norway. Advisors' Opinion:

• [By Tom Stoukas]

  Vestas Wind Systems A/S (VWS) surged 11 percent to 66.30 kroner, its highest price since February 2012. Credit Suisse Group AG raised the world�� biggest wind-turbine maker to neutral from underperform, citing benefits from cost cuts.

• [By Pato Kehoe]

  Within the power infrastructure segment, GE is especially keen on advancing in clean-energy products, such as gas and wind turbines. Wind turbines have contributed significantly to generating a solid competitive advantage, even allowing the firm to surpass the Danish industry giant Vestas Wind Systems (VWS), thanks to superior customer care and manufacturing expertise. Hence, the road seems paved for continued success in this new industry sector, which is bound to continue growing as clean energy becomes more popular.

Top Energy Companies For 2014: Susser Petroleum Partners LP (SUSP)

Susser Petroleum Partners LP is primarily engaged in fee-based wholesale distribution of motor fuels to Susser Holdings Corporation (SHC) and third parties. SHC operates over 540 retail convenience stores under its Stripes convenience store brand. In addition to distributing motor fuel, the Company also distributes other petroleum products, such as propane and lube oil, and it receive rental income from real estate that it lease or sublease. In January 2014, Susser Petroleum Partners LP announced the acquisition of the convenience store assets and fuel distribution contracts of Sac-N-Pac Stores, Inc. and 3W Warren Fuels, Ltd.

During the year ended December 31, 2011, the Company distributed 789.6 million gallons of motor fuel to Stripes convenience stores and 522.8 million gallons of motor fuel to other customers. It also distributes Chevron, CITGO, Conoco, Exxon, Mobil, Phillips 66, Shamrock, Shell, Texaco and Valero branded motor fuel, as well as unbranded motor fuel. In addition to distributing motor fuel, it also distributes other petroleum products, such as propane and lube oil.

Advisors' Opinion:

• [By Robert Rapier]

  Susser Petroleum Partners (NYSE: SUSP) engages in fee-based wholesale distribution of motor fuels. The partnership also distributes petroleum products like propane and lube oil, and receives rental income from real estate.

• [By Robert Rapier]

  Susser Petroleum Partners (NYSE: SUSP) debuted in September 2012, and has appreciated by 50 percent since. Susser engages in fee-based wholesale distribution of motor fuels. The partnership also distributes petroleum products like propane and lube oil, and receives rental income from real estate.

Top Energy Companies For 2014: Atlas Energy LP (ATLS)

Atlas Energy, L.P. (Atlas Energy), incorporated on December 15, 2005, is a limited partnership. The Company's assets consist of the Company's ownership interests in the Atlas Resource Partners, L.P. (ARP), an independent developer and producer of natural gas, crude oil and natural gas liquids (NGL), with operations in basins across the United States; Atlas Pipeline Partners, L.P. (APL) a midstream energy service provider engaged in natural gas gathering, processing and treating services in the Anandarko and Permian Basins of the United States, and Lightfoot Capital Partners, LP (Lightfoot LP) and Lightfoot Capital Partners GP, LLC (Lightfoot GP), the general partner of Lightfoot L.P. (collectively, Lightfoot), entities which incubate new master limited partnerships (MLPs) and invest in existing MLPs. As of December 31, 2012, the Company had an approximate 16% general partner interest and 12% limited partner interest in Lightfoot.

On April 30, 2012, ARP acquired 277 billion cubic feet equivalent of proved reserves, including undeveloped drilling locations, in the core of the Barnett Shale from Carrizo Oil & Gas, Inc. (Carrizo). The assets include 198 gross producing wells. On July 26, 2012, ARP acquired Titan Operating, L.L.C. (Titan), which owned approximately 250 billion cubic feet equivalent of proved reserves and associated assets in the Barnett Shale on approximately 16,000 net acres. Titan's assets are located in close proximity to the assets acquired from Carrizo in the Barnett Shale. On September 24, 2012, ARP acquired Equal Energy, Ltd�� (Equal) remaining 50% interest in approximately 8,500 net undeveloped acres. On December 20, 2012, ARP acquired 210 billion cubic feet equivalent of proved reserves in the Fort Worth basin from DTE Energy Company (DTE). The assets include 261 gross producing wells on over 88,000 net acres. The acreage position includes approximately 75,000 net acres prospective for the Marble Falls play, in which there are over 700 identified vertical drilling l! ocations..

In February 2012, APL acquired a gas gathering system and related assets, at its WestOK region. In June 2012, APL acquired a gas gathering system and related assets in the Barnett Shale in Tarrant County, Texas. In December 2012, APL acquired 100% interests held by Cardinal Midstream, LLC (Cardinal) in three wholly owned subsidiaries. The assets of these companies include gas gathering, processing and treating facilities in Arkansas, Louisiana, Oklahoma and Texas as the Tupelo plant, the East Rockpile treating facility, a fixed fee contract gas treating business, a 60% interest in Centrahoma Processing, LLC (Centrahoma), the Coalgate and Atoka plants, and the prospective Stonewall plant.

Atlas Resource Partners

During the year ended December 31, 2012, ARP�� average daily net production was approximately 77.2 million cubic feet equivalent. As of December 31, 2012, ARP owned production positions, including the Barnett Shale and Marble Falls play in the Fort Worth Basin in northern Texas; the Appalachia basin, including the Marcellus Shale and the Utica Shale; the Mississippi Lime and Hunton plays in northwestern Oklahoma, and the Chattanooga Shale in northeastern Tennessee, the Niobrara Shale in northeastern Colorado, the New Albany Shale in southwestern Indiana, and the Antrim Shale in Michigan. ARP has ownership interests in over 525 wells in the Barnett Shale and Marble Falls play. ARP has ownership interests in over 10,200 wells in the Appalachian basin, including approximately 270 wells in the Marcellus Shale. The Chattanooga Shale in northeastern Tennessee, the Niobrara Shale in northeastern Colorado, the New Albany Shale in southwestern Indiana, and the Antrim Shale in Michigan.

Atlas Pipeline Partners

APL conducts its business in the midstream segment of the natural gas industry through two reportable segments: gathering and processing, and transportation, treating and other. The gathering and processing segment consist! s of the A! rkoma, WestOK, WestTX and Velma operations, which are comprised of natural gas gathering and processing assets servicing drilling activity in the Anadarko, Arkoma and Permian Basins, and natural gas gathering assets located in the Barnett Shale play in Texas and the Appalachian Basin in Tennessee. Gathering and processing revenues are derived from the sale of residue gas and NGLs and the gathering and processing of natural gas.

APL's gathering and processing operations, own, have interests in and operate 12 natural gas processing plants with aggregate capacity of approximately 1,090 million cubic feet per day located in Oklahoma and Texas; a gas treating facility located in Oklahoma, and approximately 10,100 miles of active natural gas gathering systems located in Oklahoma, Kansas, Tennessee and Texas. APL's gathering systems gather natural gas from oil and natural gas wells and central delivery points and deliver this gas to processing plants, as well as third-party pipelines.

APL's gathering and processing operations are located in Golden Trend, Mississippian Limestone and Hugoton field in the Anadarko Basin; the Woodford Shale; the Spraberry Trend, which is an oil play with associated natural gas in the Permian Basin, and the Barnett Shale. APL's gathering systems are connected to approximately 8,600 receipt points, consisting of individual well connections and secondarily, central delivery points, which are linked to multiple wells.

APL's transportation and treating operations consists of 17 gas treating facilities used to provide contract treating services to natural gas producers located in Arkansas, Louisiana, Oklahoma and Texas, and a 20% interest in West Texas LPG Pipeline Limited Partnership (WTLPG), which owns a common-carrier pipeline system, which transports NGLs from New Mexico and Texas to Mont Belvieu, Texas for fractionation. WTLPG is operated by Chevron Pipeline Company, an affiliate of Chevron Corporation (Chevron), which owns the remaining 80% i! nterest. ! The contract gas treating operations are located in various shale plays, including the Avalon, Eagle Ford, Granite Wash, Haynesville, Fayetteville and Woodford.

The Company competes with Access Midstream Partners, LP; Caballo Energy, LLC, Carrera Gas Company; Copano Energy, LLC; Crosstex Energy Services, L.P.; DCP Midstream, LLC; Energy Transfer Partners, LP.; Enogex, LLC; Lumen Midstream Partners, LLC; MarkWest Energy Partners, L.P.; Mustang Fuel Corporation; ONEOK Field Services Company, LLC; Scissor Tail Energy, LLC; SemGas, L.P.; Southern Union Company; Superior Pipeline Company, LLC; Targa Resources Partners LP, and West Texas Gas, Inc.

Advisors' Opinion:

• [By Teresa Rivas]

  Targa Resources Partners (NGLS) is buying the oil and gas limited partnerships Atlas Pipeline Partners (APL) and Atlas Energy�(ATLS), sending the shares of both stocks up double digits.

• [By David Smith]

  Several companies, including Pittsburgh-based Atlas Energy (NYSE: ATLS  ) , appear likely to submit proposals to participate in the effort by the August deadline. Atlas has already completed 450 natural gas wells in a four-county area of Tennessee.

• [By Matt DiLallo]

  The management team at oil and gas company�Atlas Energy (NYSE: ATLS  ) has really taken Warren Buffett's advice to heart. Buffett's old adage to "be fearful when others are greedy and greedy when others are fearful" seems to be that team's approach. After selling its shale assets to Chevron at the top of the market, the company has been diligently acquiring natural gas assets at the market's low. That blueprint continues to be followed as evidenced by the recently announced acquisition of substantial natural gas assets via its master limited partnership, Atlas Resource Partners (NYSE: ARP  ) .

• [By Garrett Cook]

  Targa Resources Partners LP (NYSE: NGLS) and Targa Resources Corp (NYSE: TRGP) announced the purchase of Atlas Pipeline Partners LP and Atlas Energy LP (NYSE: ATLS) for $7.7 billion.

Top Energy Companies For 2014: Pioneer Energy Services Corp (PES)

Pioneer Energy Services Corp., formerly Pioneer Drilling Company, incorporated in 1979, provides drilling and production services to independent oil and gas exploration and production companies throughout much of the onshore oil and gas producing regions of the United States and internationally in Colombia. The Company operates in two segments: Drilling Services Division and Production Services Division. The Company�� Drilling Services Division provides contract land drilling services. The Company�� Production Services Division provides a range of services to oil and gas exploration and production companies. On December 31, 2011, the Company acquired Go-Coil, LLC.

Drilling Services Division

The Company�� Drilling Services Division provides contract land drilling services with its fleet of 64 drilling rigs in South Texas, East Texas, West Texas, North Dakota, North Texas, Utah, Appalachia and Colombia. As of February 10, 2012, 55 drilling rigs are operating under drilling contracts, 44 of which are under term contracts. In 2011, the Company established its West Texas drilling division location location where it has 18 drilling rigs operating. In addition to its drilling rigs, the Company provides the drilling crews and the ancillary equipment needed to operate its drilling rigs. Its drilling contracts provide for compensation on either a daywork, turnkey or footage basis.

As of February 10, 2012, the Company owned a fleet of 54 trucks and related transportation equipment that it uses to transport its drilling rigs to and from drilling sites. Under daywork drilling contracts, it provides a drilling rig and required personnel to its customer who supervises the drilling of the well. Under a turnkey contract, the Company agrees to drill a well for its customer. It provides technical and engineering services, as well as the equipment and drilling supplies required to drill the well. The Company often subcontracts for related services, such as the provision of cas! ing crews, cementing and well logging. Under footage contracts, it is paid a fixed amount for each foot drilled.

The Company competes with Helmerich & Payne, Inc., Precision Drilling Trust, Patterson-UTI Energy, Inc. and Nabors Industries, Ltd.

Production Services Division

The Company�� Production Services Division provides a range of services to oil and gas exploration and production companies, including well services, wireline, coiled tubing and fishing and rental services. Its production services operations are managed through locations concentrated in the United States onshore oil and gas producing regions in the Gulf Coast, Mid-Continent, Rocky Mountain and Appalachian states. The Company provides its services to a diverse group of oil and gas exploration and production companies. Under well services, it provides rig-based well services, including maintenance of existing wells, workover of existing wells, completion of newly-drilled wells, and plugging and abandonment of wells at the end of their useful lives.

The Company provides wireline services in Texas, Kansas, Colorado, Utah, Montana, North Dakota, Louisiana, West Virginia, Wyoming and Mississippi. The Company�� Coiled tubing is used for a number of horizontal well applications such as milling temporary plugs between frac stages. Its coiled tubing business consists of ten coiled tubing units which are deployed in Texas, Louisiana, Oklahoma and Pennsylvania. The Company�� rental and fishing tool business provides a range of specialized services and equipment that are utilized on a non-routine basis for both drilling and well servicing operations. It provides rental services out of four locations in Texas and Oklahoma. As of February 10, 2012, the Company had a total of 91 well service rigs. Its well service rig fleet consists of eighty-one 550 horsepower rigs, nine 600 horsepower rigs, and one 400 horsepower rig. As of February 10, 2012, the Company had 109 wireline units in 24 locations.

The Company competes with Key Energy Services, Basic Energy Services, Nabors Industries, Superior Energy Services, Inc,

CC Forbes, Schlumberger Ltd., Halliburton Company, Weatherford International, Baker Hughes, Superior Energy Services, Basic Energy Services, and Key Energy Services, Quail Tools and Knight Oil Tools.

Advisors' Opinion:

• [By Chuck Carnevale]

  However, from 2002 to current time we see a conflicting relationship between interest rates and stock prices. In this case, as interest rates continued to decline, stock valuations (PEs) followed suit and declined as well. In theory, this should not happen. Because with interest rates so low, as a practical matter bonds become less competitive to stocks, but even worse, today bonds don�� even offer any real return. This is especially true when you compare blue-chip dividend yields available from stalwarts such as PepsiCo (PEP), Proctor & Gamble (PG), and Johnson & Johnson (JNJ), etc., to interest rates. For the first time since I can remember, these companies are offering higher dividend yields than not only the 10-year Treasury but the 30-year as well.

• [By Lee Jackson]

  Pioneer Energy Services Corp. (NYSE: PES) is another small cap name that could be a huge home run for investors in 2014. The company provides contract land drilling services and production services to independent and oil and gas exploration and production companies in the United States and Colombia. The company operates in two segments, Drilling Services and Production Services. The Deutsche Bank price target is a whopping $14, and the consensus is much lower at $9.50. Pioneer Energy closed Monday at $8.

• [By Chuck Carnevale]

  Therefore, risk and earnings growth rates will represent counteracting forces affecting starting or current valuation (PEs). This partially explains why a 3% grower (less risky to achieve) might command the same current valuation PE of, for example, an 11% or 12% grower (riskier and harder to achieve). But this is a critical point; the faster grower will generate a higher future return than the slower grower, ceteris paribas.

Top Energy Companies For 2014: ATP Oil And Gas Corp (AOB)

ATP Oil & Gas Corporation, incorporated in 1991, is engaged in the acquisition, development and production of oil and natural gas properties. As of December 31, 2011, the Company had estimated net proved reserves of 118.9 Million barrels of crude oil equivalent (MMBoe), of which approximately 75.9 MMboe (64%) were in the Gulf of Mexico and 42.9 MMBoe (36%) were in the North Sea. The reserves consisted of 78.6 Million barrels (MMBbls) of oil (66%) and 241.5 billion cubic feet (Bcf) of natural gas (34%). Its proved reserves in the deepwater area of the Gulf of Mexico account for 62% of the Company�� total proved reserves and its proved reserves on the Gulf of Mexico Outer Continental Shelf account for 2% of its total proved reserves. During the year ended December 31, 2011, the Company acquired three licenses in the Mediterranean Sea covering potential natural gas resources in the deepwater off the coast of Israel (East Mediterranean). On August 17, 2012, ATP Oil And Gas Corp filed for Chapter 11 bankruptcy protection.

The Company�� natural gas reserves are split between the Gulf of Mexico (57%) and the North Sea (43%). Of its total proved reserves, 8.3 MMBoe (7%) were producing, 19.0 MMBoe (16%) were developed and not producing and 91.6 MMBoe (77%) were undeveloped. The Company�� average working interest in its properties at December 31, 2011, was approximately 81%. The Company operates 92% of its platforms. At December 31, 2011, in the Gulf of Mexico, it owned leasehold and other interests in 38 offshore blocks and 49 wells, including 23 subsea wells. The Company operates 43 (88%) of these wells, including 100% of the subsea wells. In the North Sea, it also had interests in 13 blocks and two Company-operated subsea wells. As of March 15, 2011, the Company owned an interest in 13 platforms, including two floating production facilities in the Gulf of Mexico, the ATP Titan at its Telemark Hub and the ATP Innovator at its Gomez Hub. It operates the ATP Innovator and the ATP Titan.

Advisors' Opinion:

• [By John Emerson]

  Most of the Chinese companies that I purchased now reside on the Pink Sheets or have disappeared altogether, but at one time they all traded on major US exchanges. One of them (AOB), even received the honor of ringing the opening bell at the New York Stock Exchange in 2007, and people say that crime does not pay.

Top 10 Low Price Companies To Buy For 2015

Top 10 Low Price Companies To Buy For 2015: Fomento de Construcciones y Contratas SA (FCC)

Fomento de Construcciones y Contratas SA (FCC) is a Spain-based company, which is primarily engaged, together with its subsidiaries in the construction and environmental services sector. The Company's activities include the collection, treatment and elimination of solid urban waste, street cleaning, sewer system maintenance, green areas and buildings maintenance, urban transport, treatment and elimination of industrial waste, full-service water supply management and cement manufacture. The Company is also active in the real estate development, as well as in the renewable energy industry. In addition, the Company is a parent of Grupo FCC, a group which comprises a number of controlled entities. Advisors' Opinion:

• [By Quick Pen]

  The Federal Communications Commission (FCC) and the Department of Justice (DoJ) do not want the number of players in the telecom sector to shrink below four – Verizon, AT&T, Sprint, and T-Mobile. To this Sprint's Son argues that the industry already has four players – Verizon that purchased Vodafone's stake in it, AT&T which plans to acquire DirecTV (DTV), and Comcast (CMCSA); Sprint would be the fourth one. But these antitrust issues have been a challenge for Sprint.

• [By Live Investor]

  What does the FCC have to say? The regulator's reaction is nothing surprising. After Son met the Federal Communications Commission (FCC) to convince them about the prospects of the proposed deal, Reuters reported that FCC chairman Tom Wheeler wasn't quite impressed and had dubious thoughts on it.

source from Top Stocks For 2015:http://www.topstocksblog.com/top-10-low-price-companies-to-buy-for-2015-3.html

Top 10 Safest Companies To Watch For 2015

Top 10 Safest Companies To Watch For 2015: CYNK Technology Corp (CYNK)

Cynk Technology Corp., formerly Introbuzz, Inc., is a development stage-company. The Company intends to develop a social network business. Social networks are Web based services that allow individuals to post a profile and link their profile to other friends and organizations.

The Company intends to develop a database of professional and other business persons, as well as other interested persons in providing and utilizing contacts. As of November 14, 2012, the Company had not generated any revenue.

Advisors' Opinion:

• [By WWW.DAILYFINANCE.COM]

  CYNK Technology (CYNK), the mysterious over-the-counter stock that at one point broke a $6 billion market cap, dropped roughly 80 percent in its first trades after a Securities and Exchange Commission halt. The SEC halted CYNK for two weeks following a massive rise in the stock's value -- it had been worth only a few cents per share in June, but it jumped above $21 on July 10. The Belize-based CYNK Technology supposedly operates a social networking site, but filings indicate it only has one employee and virtually no assets. Experts told CNBC the week of the SEC halt that they expected CYNK to fall precipitously after reopening, and its first day of trading is proving those predictions correct. When it was halted, the stock was worth just less than $14 per share, and is now below $3 a share after briefly hovering around $5 earlier Friday morning. An OTC Markets spokeswoman told Reuters that CYNK's shares were not trading on its platform, but were occurring over the phone. Earlier this week Reuters reported that OTC's CEO did not expect CYNK to trade on its platform at all after reopening, as no brokerages would file the required paperwork for the stock to trade on their exchanges. An SEC spokesman said that the organization cannot comment on the! status of a company after a suspension period ends, citing an online explanation of the process. That document notes that broker-dealers may not solicit investors to trade the previously suspended OTC stock until they satisfy several regulatory requirements. The SEC warned, however, that "unsolicited" trading may occur after a reopening -- as CYNK is now seeing -- but "even though such trading is allowed, it can be very risky for investors without current and reliable information about the company."

source from Top Stocks For 2015:http://www.topstocksblog.com/top-10-safest-companies-to-watch-for-2015.html

New Wearable Fitness Tracker Debuts at Just $1 a Month

Best Canadian Stocks To Invest In Right Now

www.pivotalliving.com It's about to get a lot cheaper to track your fitness activity, calories burned and sleep patterns. The Life Tracker 1 will begin shipping later this year, costing just $12 a year for the wristband hardware and access to the reporting software app. Pivotal Living is the company behind the low-cost entry into the crowded and competitive fitness tracking niche. The Seattle-based upstart is helmed by a former Microsoft (MSFT) employee, but the real head-turning aspect of the Life Tracker 1's debut is its price. Today's most popular fitness bracelets start at $60, with more advanced models selling north of $100. You're going to generate plenty of buzz if you hit the market with a wearable device given away with the $12 annual app subscription. Catching Up in a Hurry The fitness tracker market has been dominated by Fitbit and Jawbone for years. Nike (NKE) tried to give it a go with its Nike+ FuelBand. The $149 fitness bracelet got off to a strong start two years ago with its high-tech device that uses a three-axis accelerometer to track movements using a proprietary NikeFuel metric of measurement. However, it failed to gain traction, and Nike went on to lay off the majority of the FuelBand's hardware team in April, discontinuing a slimmer model that was supposed to hit the market this year. Nike is the undisputed champ of athletic footwear and apparel, but sometimes a killer brand isn't enough. We've seen that with Samsung (SSNLF) and Garmin (GRMN) with their recent push into wearables, and in a few weeks, we'll see Apple (AAPL) give it a shot with its Apple Watch. Apple is gunning for the high end of the wearables market with a smartwatch starting at $349. That device will of course, track fitness activity, but its major selling points are how it plays nice with smartphones to serve up calls, notifications, text messages and even select app interactions. Big tech sees big money in grabbing you by the wrist, but that trend also represents an opportunity for a hungry upstart like Pivotal Living, with all of nine employees, as it tries to get its fledgling platform off the ground. Life Tracker 1 or Life Tracker Won? Skeptics will argue that you will be getting what you pay for, but the Life Tracker 1 will do plenty for that annual $12 subscription. Let's go over the features tracked or displayed on the wristband, according to the press release. Calories burned Sleep length Total steps Sleep quality Distance Hydration Daily active time Weight Percentage met of daily goals The tracking wristband will need to be charged every five to seven days, and a manual sync every three days or so will pass on the information to your smartphone or tablet to store historical data. The app for Android and iOS devices will be available in early November. Tools will promote engagement by having owners create teams with friends, but we already know that the social element that differentiated Nike over the competition wasn't a game changer. Then again, Nike never attempted to hit the market at the radical price point that we're seeing here. If the low price makes the Life Tracker 1 a hot stocking stuffer this holiday season, there could be some viral magic in its corner. The price is right. The mobile health tech niche is emerging. It's a fitness tracker that the market will be watching, but we can never forget that there are bigger companies out there that are hungry for a piece of this booming market. More from Rick Aristotle Munarriz
•Last Week's Top Stock Movers: Flags Flew, Floors Went Down •Wall Street This Week: Fun Stuff Makes Financial News •Week's Winners and Losers: Tough Sell for Some Gadgets

Top 10 Biotech Stocks To Watch For 2014

Popular Posts: Hottest Energy Stocks Now – HK QEP CLMT SDRL13 “Triple A” Stocks to Buy7 Biotechnology Stocks to Buy Now Recent Posts: Hottest Healthcare Stocks Now – CAH PDLI SHPG FRX Hottest Technology Stocks Now – CYOU HPQ NCR MSFT Biggest Movers in Financial Stocks Now – RDN AIG MTG MFG View All Posts

This week, these five stocks have the worst ratings in Earnings Growth, one of the eight Fundamental Categories on Portfolio Grader.

BlackBerry Limited () engages in the design, manufacture and marketing of wireless solutions worldwide. BBRY also gets F’s in Earnings Momentum, Analyst Earnings Revisions, Equity, Cash Flow and Sales Growth. .

Top 5 Small Cap Stocks To Watch Right Now: Puma Biotechnology Inc (PBYI)

Puma Biotechnology, Inc., incorporated in April 2007, is a development-stage biopharmaceutical company that acquires and develops products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. As of December 31, 2011, the Company licensed three drug candidates: PB272 (neratinib (oral)), which the Company is developing for the treatment of advanced breasts cancer patients and gastric cancer patients; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of advanced cancer patients, and PB357.

PB272 (neratinib (oral))-Breast Cancer

Neratinib is a potent irreversible tyrosine kinase inhibitor, or TKI, that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. The Company's initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer.

PB272 (neratinib (intravenous))

The Company develops neratinib as an intravenously administered agent. In pre-clinical studies the intravenous version of neratinib resulted in higher exposure levels of neratinib in pre-clinical models.

PB357

PB357 is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. PB357 is structurally similar to PB272. Pfizer completed single dose Phase I trials of PB357. The Company is evaluating PB357.

The Company competes with Genentech, GlaxoSmithKline, Roche, Boehringer Ingelheim, Takeda, Array Biopharma and Ambit Biosciences.

Advisors' Opinion:

• [By Anna Prior]

  Puma Biotechnology Inc.(PBYI) reported positive top-line data from the Phase II clinical trial of the biopharmaceutical company’s investigational drug PB272 for the neoadjuvant treatment of breast cancer.

• [By Ben Levisohn]

  The Dow Jones Industrial Average and S&P 500 squeaked out new highs today, while the Nasdaq Composite and small caps dropped, following stronger-than-forecast manufacturing data out of China and a U.S. manufacturing survey that had to be corrected twice. Caterpillar (CAT) and Broadcom�(BRCM) gained, while Express Scripts (ESRX) and Puma Biotechnology (PBYI) tumbled.

• [By Lee Jackson]

  Puma Biotechnology Inc. (NYSE: PBYI) is a stock that UBS views as having multiple catalysts. The analysts are positive on the potential for their cancer drug neratinib to demonstrate positive data in neoadjuvant breast, as well as specific genetic mutations for other cancers. Success in either area may lead to strong upside for the stock. The UBS price target is $61, while consensus is at $62.50.

Top 10 Biotech Stocks To Watch For 2014: Intrexon Corp (XON)

Intrexon Corporation, incorporated on April 19, 2004, is engaged in the business of synthetic biology. Using the Company�� suite of complementary technologies, it design, build and regulate gene programs, or sequences of deoxyribonucleic acid (DNA) that control cellular function, and cellular systems, or activities that take place within a cell and the interaction of those systems in the greater cellular environment, to enable the development of new and improved products and manufacturing processes across a variety of end markets, including healthcare, food, energy and environmental sciences. Its technologies include the UltraVector gene design and fabrication platform; Cell Systems Informatics; LEAP-cell identification and selection, and mAbLogix-antibody discovery.

The Company�� LEAP technology facilitates the automated identification of an individual cell with the highest levels of expression, quality and potency from a population of over 100,000 cells. Its mAbLogix platform complements UltraVector with a library of human antibodies that exceeds 500 million. By immortalizing human tonsils, which consists of lymphatic tissue containing B-cells, its mAbLogix platform creates a B-cell library that can generate antibodies against an almost infinite number of new antigens.

The UltraVector gene design and fabrication platform

The Company�� gene program design platform, which it refer to as UltraVector, is an integrated suite of tools comprising advanced DNA construction technology and components, cellular and protein engineering tools, computational models and statistical methods which facilitate the rapid design, build and testing of complex systems. The UltraVector platform allows the Company to translate gene programs into standard components that can be designed, manufactured and tested in an automated format. This technology enables it to engineer at the cellular level from biological sources.

UltraVector DNA design is computer-automated and ! utilizes a set of defined construction rules to assemble components that are stored in its DNA library. In addition to the number of gene components in its UltraVector library, it is designing and creating enzymatic and regulatory components that provide control over genome integration and gene regulation. Its RheoSwitch Therapeutic System is a three-component transcriptional regulator that provides inducible gene expression. The RheoSwitch Therapeutic System provides the ability to not only express proteins/enzymes of interest, but also the ability to control the level and timing of expression to achieve a biological outcome. Other ongoing programs include its Attsite recombinases, which mediate predictable gene exchange into host cells thereby eliminating many of the difficulties seen with traditional gene insertion.

Cell Systems Informatics

The Company�� Cell systems informatics permits design, as well as testing and learning about new gene targets or product pathways. Its bioinformatics software and database systems for mapping cellular pathways when combined with its genome-scale modeling and experimental data, including, gene expression profiling and protein engineering, enable the Company to optimize selection and development of gene programs and cellular systems for its collaborators. Its computational modeling and simulation platform enables the development of predictive computer models of organisms, from microbes to humans. This platform builds virtual cells from their basic molecular components, and can simulate the activity of the cell�� complete reaction network.

The Company is designing proteins with post-translational modifications. It is also working to develop enzyme inhibitors and fusion proteins for a variety of applications in human and animal therapeutics. Its protein engineering may utilize one or more of its technologies to obtain catalysis activitiesits component library, the generation of component variants sequence, evolutionary analy! sis and s! tructure-based sequence alignment, computer-aided drug discovery, de novo, or synthesized or generated, and comparative protein modeling, molecular dynamics simulation and free energy analysis, antibody design and humanization, antigenicity prediction, protein pharmacokinetics optimization, and/or in silico support of enzyme engineeringand quantitative structure-function relationships with machine learning algorithms to optimize, facilitate and prioritize protein variant libraries for the advancement of its collaborators.

LEAP-cell identification and selection

The Company�� Laser-Enabled Analysis and Processing technology (LEAP), is an instrument that merges semiconductor manufacturing technologies for cell processing applications to provide high levels of control and scale to cell purification and stem cell culture management. The LEAP platform can identify and purify cells of interest from large libraries of cells created by its UltraVector and bioinformatics technologies using a laser-based purification process, thereby providing a mechanism of testing the degree of protein expression in genetically modified cells, as well as means to learn from the genetic building process.

mAbLogix- antibody discovery

The Company�� mAbLogix antibody discovery platform, or mAbLogix platform, enables production of B-cell libraries for discovery of antibodies. The mAbLogix platform permits antigen targeting using fully human monoclonal and polyclonal antibodies. Its mAbLogix antibody discovery process consists of two major activities: the build of human B-cell libraries expressing a large number of antibodies, and the testing of these libraries based on an analysis of B-cells that express antibodies in response to a chosen antigen.

The Company competes with AbD SeroTec, Alexion Pharmaceuticals, Inc., XOMA Corporation, Genmab US, Inc., MorphoSys AG, NovImmune SA, Societe Des Systemes Biologiques, Adimab, LLC, ProMab Biotechnologies, Inc., Abpro, Inc.,! AIIM The! rapeutics and Open Monoclonal Technology, Inc.

Advisors' Opinion:

• [By John Udovich]

  Bubble talk, biotech IPO setbacks plus news�about small cap biotechs like Intrexon Corp (NYSE: XON) and TNI BioTech (OTCMKTS: TNIB) have dominated biotech news this week or in recent weeks. Just consider the following news:

• [By Jon C. Ogg]

  Intrexon Corp. (NYSE: XON) was started as Buy at Mizuho Securities, started as Equal Weight at Barclays and started as Overweight at J.P. Morgan.

  Nokia Corp. (NYSE: NOK) was raised to Hold from Sell at Deutsche Bank, raised to Neutral from Underperform at Credit Suisse and
  Canaccord Genuity raised its price target to $5.50 from $3.30.

Top 10 Biotech Stocks To Watch For 2014: OncoMed Pharmaceuticals Inc (OMED)

OncoMed Pharmaceuticals, Inc. (OncoMed) incorporated on July 19, 2004, is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing monoclonal antibody therapeutics targeting cancer stem cells (CSCs). It utilizes its technologies to identify, isolate and evaluate CSCs; identify and/or validate multiple potential targets and pathways critical to CSC self-renewal and differentiation; and develop targeted antibody and other protein-based therapeutics that are designed to modulate these CSC targets and inhibit the growth of CSCs. The Company's anti-cancer therapeutics include anti-DLL4 (demcizumab, OMP-21M18), Anti-DLL4/Anti-VEGF Bispecific, and Anti-Notch2/3 (OMP-59R5), Anti-Notch1 (OMP-52M51, Anti-Fzd7, Fzd8-Fc, RSPO-LGR.

Anti-DLL4 (demcizumab, OMP-21M18) is a humanized monoclonal antibody that inhibits Delta Like Ligand 4 (DLL4) in the Notch signaling pathway. The Company has completed a single-agent Phase Ia trial in advanced solid tumor patients. The Company focuses on conducting two Phase Ib combination trials of demcizumab. Anti-DLL4/anti-VEGF bispecific is a monoclonal antibody that targets and inhibits both DLL4 and vascular endothelial growth factor ( VEGF). VEGF is the target of Avastin. Anti-Notch2/3 (OMP-59R5) is a human monoclonal antibody that targets the Notch2 and Notch3 receptors.

Anti-Notch1 OMP-52M51 is a humanized monoclonal antibody targeted to the Notch1 receptor. Anti-Fzd7 OMP-18R5 is a human monoclonal antibody identified by screening against the Frizzled7 receptor (Fzd7) that binds a conserved epitope on five Frizzled receptors and inhibits Wnt signaling. OMP-18R5 is in a Phase I single-agent trial in advanced solid tumor patients. Fzd8-Fc OMP-54F28 is a fusion protein based on a truncated form of the Frizzled8 receptor ( Fzd8). RSPO-LGR ligands signal through the LGR receptor family.

The Company utilizes several robust technologies for the discovery and optimization of its antibody and protein-bas! ed therapeutics, including multiple proprietary technologies. Its antibody technologies include Mammalian Display Technology, Bispecific Antibody Technology, Hybridoma Technology. Mammalian Display Technology utilizes flow cytometry to isolate mammalian cells expressing antibodies on the cell surface with desired characteristics from large libraries of candidate antibodies. Bispecific Antibody Technology is used to generate its anti-DLL4/anti-VEGF antibody. Hybridoma Technology is used for isolating antibodies from mice, including multiplex single-cell screening techniques.

Advisors' Opinion:

• [By Stephen Quickel]

  Recently, too, Celgene has formed a strategic partnership with OncoMed (OMED) to develop up to six anti-cancer stem-cell antibodies.

  Celgene itself has posted four successive quarters of revenue growth, which is expected to lift annual sales from $5.5 to $6.4 billion for calendar 2013, and to $7.5 billion in 2014. Despite its expanding size, earnings per share are projected to grow by 23.2% a year, by 28 Street analysts following its stock.

• [By Roberto Pedone]

  OncoMed Pharmaceuticals (OMED), a clinical development-stage biotechnology company, focuses on discovering and developing monoclonal antibody therapeutics targeting cancer stem cells. This stock closed up 5.3% at $18.08 in Monday's trading session.

  Monday's Volume: 446,000
  
  Three-Month Average Volume: 178,792
  
  Volume % Change: 155%

  From a technical perspective, OMED ripped higher here right above previous support at $16.57 with above-average volume. This stock has been downtrending badly for the last four months and change, with shares moving lower from its high of $28.43 to its recent low of $16.57. During that move, shares of OMED have been making mostly lower highs and lower lows, which is bearish technical price action. That said, shares of OMED have now starting to rebound off some previous support and it's quickly moving within range of triggering a near-term breakout trade. That trade will hit if OMED manages to clear some near-term overhead resistance levels at $19.17 to its 50-day at $19.92 and then above more resistance at $20 with high volume.

  Traders should now look for long-biased trades in OMED as long as it's trending above some key near-term support at $16.57 and then once it sustains a move or close above those breakout levels with volume that hits near or above 178,792 shares. If that breakout kicks off soon, then OMED will set up to re-test or possibly take out its next major overhead resistance levels at $21.80 to $22.43, or even $24 to $24.48.

• [By WWW.DAILYFINANCE.COM]
  Stocks ended a mini-losing streak on Friday, led by upbeat news from Intel (INTC). The Dow Jones industrial average (^DJI) rose 41 points, after sliding more than 200 over the previous two days. The Nasdaq composite (^IXIC) gained 13 and the Standard & Poor's 500 index (^GPSC) added 6 points. Those modest gains did little to trim the loss for the week. The major averages posted their biggest weekly declines in more than two months. Intel is a component of all three big indexes, and it jumped 7 percent after raising its revenue guidance for the current quarter. The company sees stronger business demand for PCs than it previously expected. Intel shares are up 23 percent over the past six months. The Intel news had a ripple effect. Computer maker Hewlett-Packard (HPQ) rose more than 5 percent and Microsoft (MSFT) gained 1½ percent. Part of the increased demand Intel points to is tied to corporate buyers who need to replace their Windows XP machines, because Microsoft has stopped providing technical support for that platform. But Apple (AAPL) lost more than 1 percent. The stock is down since its 7-for-1 stock split took effect on Monday. There were two other big stories that had some legs beyond the companies directly involved. Open Table (OPEN) agreed to be acquired by Priceline (PCLN) for $2.6 billion. Open Table, which provides restaurant reservations, jumped 48 percent. Other online service providers rode the coattails of that deal. Yelp (YELP) gained 14 percent and Groupon (GRPN) gained 4 percent. In the retail arena, Express (EXPR) jumped 21 percent after a private equity firm took a 9.9 percent stake in the teen retailer and indicated it may make a buyout offer. That gave a boost to Aeropostale (ARO) and American Eagle (AEO), which both rose more than 2 percent. Abercrombie & Fitch (ANF) gained 1½. Elsewhere, International Game Technology (IGT) gained 10½ percent on a Reuters report that a bidding war could erupt for
• [By Jake L'Ecuyer]

  Equities Trading UP
  OncoMed Pharmaceuticals (NASDAQ: OMED) shot up 8.62 percent to $30.09 after the company initiated Phase 1B trial of WNT-parthway-target antibody. Jefferies lifted the price target on the stock from $27 to $46.

Top 10 Biotech Stocks To Watch For 2014: Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc. (Oncolytics), incorporated on April 2, 1998, is a development-stage company. The Company is focused on its research and development of REOLYSIN, which is its cancer therapeutic. REOLYSIN is developed from the reovirus. This virus has been demonstrated in tumour cells bearing an activated Ras pathway. Oncolytics is directing a clinical trial program with the focus of developing REOLYSIN as a human cancer therapeutic. The clinical program includes clinical trials, which it sponsors directly along with Third Party Clinical Trials. Third Party Clinical Trials are clinical trials that are being sponsored by other institutions. As of December 31, 2011, the United States National Cancer Institute (NCI), the University of Leeds and the Cancer Therapy & Research Center at the University of Texas Health Center in San Antonio (CTRC) were sponsoring part of its clinical trial program.

The Company�� clinical trial program has included human trials using REOLYSIN alone, and in combination with radiation and chemotherapy, and delivered via local administration and/or intravenous administration. Oncolytics uses contract toll manufacturers to produce REOLYSIN. On December 31, 2011, the Company had two wholly owned subsidiaries, Oncolytics Biotech (Barbados) Inc. (OBB) and Valens Pharma Ltd. Oncolytics Biotech (US) Inc. and Oncolytics Biotech (U.K.) are wholly owned subsidiaries of OBB.

Advisors' Opinion:

• [By Maxx Chatsko]

  T-VEC is not your traditional biologic drug. It is actually a bioengineered form of the herpes virus that, once injected into cancerous tumors, replicates, and produces an immune-stimulating protein that puts a bulls eye on cancer cells throughout the body. Despite its promise and intriguing mechanism of action, T-VEC is not in further development at Amgen. However, Oncolytics (NASDAQ: ONCY  ) has shown promising results for its bioengineered form of reovirus called Reolysin. Initial phase 3 results showed that 86% of patients taking the drug had reduced tumor mass or growth after six weeks of treatment. �

Top 10 Biotech Stocks To Watch For 2014: Cytomedix Inc (CMXI)

Cytomedix, Inc. (Cytomedix), incorporated in April 29, 1998, is a regenerative therapies company marketing and developing products within the United States and internationally .The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company is a commercial operation, and a robust clinical pipeline representing a logical extension of its commercial technologies in the evolving field of regenerative medicine. Cytomedix primarily operates in the United States. Its commercial offerings are centered on its point of care platform technologies for the safe and efficient separation of blood and bone marrow to produce platelet based therapies or cell concentrates.

The Company markets and selsl two distinct platelet rich plasma (PRP) technologies, the AutoloGel System for wound care and the Angel concentrated Platelet Rich Plasma (cPRP) Sytem in orthopedic and cardiovascular markets. Its clinical pipeline includes the ALDH, which are cell-based therapies (Bright Cells). In February 2012, the Company acquired Aldagen, Inc.

The AutoloGel System

The AutoloGel System is a point of care device for the production of a platelet based bioactive therapy derived from a small sample of the patient�� own blood. Using the patient�� own platelets as a therapeutic agent, AutoloGel harnesses the body�� natural healing processes to deliver growth factors, chemokines and cytokines known to promote angiogenesis and to regulate cell growth and the formation of new tissue.

Angel Product Line

The Angel concentrated Platelet Rich Plasma (cPRP) System is a multi-functional cell separation device which produces concentrated platelet rich plasma for use in the operating room and clinic and is used in a range of orthopedic and cardiovascular indications. Similar to the AutoloGel System, the Angel System is a point of care device for the production of a concentrated, aseptic platelet! -based bioactive therapy derived from a small sample of the patient�� own blood. The resulting cPRP is applied at the site of injury to promote healing. The Angel product line also includes ancillary products such as phlebotomy and applicator supplies and activAT. activAT is designed to produce autologous thrombin serum from platelet poor plasma and is sold exclusively in Europe and Canada, where it provides a safe alternative to bovine-derived products.

ALDHbr Cell Technology and Development Pipeline

The ALDHbr (Bright Cell) technology is an approach to cell-based regenerative medicine and a logical extension of its commercial technologies in the evolving regenerative medicine market, with potential clinical indications in markets with unmet medical needs such as peripheral arterial disease and ischemic stroke. The Bright Cell technology is in that it utilizes an intracellular enzyme marker to facilitate fractionation of essential regenerative cells from a patient�� bone marrow. The bone marrow fractionation process identifies and isolates active stem and progenitor cells expressing high levels of the enzyme aldehyde dehydrogenase, or ALDH, which is a key enzyme involved in the regulation of gene activities associated with cell proliferation and differentiation.

The Company�� lead product candidate, ALD-401, is an autologous preparation of Bright Cells for the post-acute treatment of ischemic stroke. ALD-401 is being evaluated in the RECOVER-Stroke clinical study, an ongoing 100-patient, double-blind, placebo-controlled Phase 2 study in patients with unilateral, cerebral ischemic stroke with an NIH stroke scale score of less than 22. An additional product candidate, ALD-301, is in clinical development for peripheral arterial disease (PAD), a condition causing reduced flow of blood and oxygen to muscles in the leg. It has completed a Phase 1/2 study of autologous ALD-301 in critical limb ischemia (CLI), a late stage condition caused by PAD. The Phase 2 PACE! (Patient! s with Intermittent Claudication Injected with ALDH Bright Cells) study is an 80 patient, double-blind, placebo-controlled clinical trial intended to demonstrate the safety and efficacy of ALD-301 (Bright Cells) in patients diagnosed with IC.

The Company competes with Harvest Technologies (a subsidiary of Terumo), Biomet, Arteriocyte, and Arthrex.

Advisors' Opinion:

• [By Bryan Murphy]

  When traders think of post-surgical wound management stocks, they may first think of names like Cytomedix, Inc. (OTCBB:CMXI) or Alliqua Inc. (OTCMKTS:ALQA). And well they should. Both companies have something of a history in the arena. ALQA is the purveyor of SilverSeal and Hydress antibiotic bandages, while CMXI is the developer of the AutoloGel system, which induces an affected patient's on body to do what it's supposed to do if there's a wound that won't heal. Cytomedix also makes the Angel platelet-rich plasma (PRP) delivery system. There's a relatively new name to add to the list of game-changing stocks in wound-management industry, however.... Arch Therapeutics Inc. (OTCBB:ARTH). The company is developing - well, has developed - a product called AC5 that nips post-surgical bleeding in the bud, largely negating the need for other post-surgical bleeding-control measures.

Top 10 Biotech Stocks To Watch For 2014: Alcobra Ltd (ADHD)

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse. MG01CI product has completed phase two studies. Advisors' Opinion:

• [By Roberto Pedone]

  A biopharmaceutical stock that's starting to trend within range of triggering a big breakout trade is Alcobra (ADHD), which is engaged in the development and commercialization of its proprietary drug, MG01CI, to treat attention deficit hyperactivity disorder. This stock has been on fire so far in 2013, with shares up huge by 126%.

  If you take a look at the chart for Alcobra, you'll notice that this stock has been trending sideways and consolidating over the last month and change, with shares moving between $14.78 on the downside and $18.75 on the upside. Shares of ADHD have now started to uptrend a bit over the last few weeks, with shares moving higher from its low of $15.05 to its recent high of $18.45 share. That move has started to push shares of ADHD within range of triggering a big breakout trade above the upper-end of its recent sideways trading chart pattern.

  Traders should now look for long-biased trades in ADHD if it manages to break out above its 50-day moving average of $17.79 a share, and then once it takes out some more key overhead resistance levels at $18.45 to $18.75 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 74,869 shares. If that breakout triggers soon, then ADHD will set up to re-test or possibly take out its next major overhead resistance levels at $22 to $24 a share. Any high-volume move above those levels will then give ADHD a chance to re-test or possibly take out its all-time high at $26.96 a share.

  Traders can look to buy ADHD off any weakness to anticipate that breakout and simply use a stop that sits right below some near-term support levels at $16.17 to $15.05 a share, or around $14.78 a share. One could also buy ADHD off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By MONEYMORNING.COM]

  For example, a phase 3 clinical trial on metadoxine extended release as a treatment for adult attention deficit hyperactivity disorder (ADHD) will be finishing up at the end of this year. Positive data could give the stock a huge boost.

Top 10 Biotech Stocks To Watch For 2014: Cell Therapeutics Inc (CTIC)

Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisition gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.

Pixuvri

As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed complete response compared to patients treated with standard chem! otherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.

OPAXIO

OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces responsiveness to TMZ. A phase I/II study of OPAXIO combined with radi! otherapy ! and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.

Tosedostat

In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic syndrome (MDS), a precursor of AML.

Brostallicin

As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).

The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Celgene, Telik, I! nc., TEVA! Pharmaceuticals Industries Ltd. and PharmaMar.

Advisors' Opinion:

• [By John Udovich]

  The start of 2014 shows that biotech is still a hot area with the sector along with small cap biotech stocks like AMAG Pharmaceuticals, Inc (NASDAQ: AMAG), Mast Therapeutics Inc (NYSEMKT: MSTX), Cell Therapeutics Inc (NASDAQ: CTIC), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and TNI BioTech (OTCMKTS: TNIB) producing news or returns�plus Auspex Pharmaceuticals (NASDAQ: ASPX), Cara Therapeutics (NASDAQ: CARA), Egalet (NASDAQ: EGLT), Flexion Therapeutics (NASDAQ: FLXN) and Ultragenyx Pharmaceutical (NASDAQ: RARE) are among the (many�� planned biotech IPOs that have recently been announced publicly:

• [By Sean Williams]

  Cell Therapeutics (NASDAQ: CTIC  )
  Certainly no discussion of companies with large accumulated deficits would be complete without discussing a biotechnology company. It's perfectly understandable to see a biotech, especially a clinical-stage one, run with an accumulated deficit, as it takes time and money to build up a drug pipeline. However, after multiple complete response letters (the equivalent of a rejection) by the Food and Drug Administration and years without an approved drug, Cell Therapeutics racked up an astounding $1.83 billion in accumulated deficits through the end of fiscal 2012. By comparison, that's nearly 56 times larger than its shareholder equity.�

• [By Bryan Murphy]

  Like it or not, all good things must come to an end.... even for a red hot stock like Cell Therapeutics Inc. (NASDAQ:CTIC). Yes, CTIC is up 111% since the end of 2013, up 14% today alone, and it doesn't look like the bulls have any reason to slow down now. That's exactly why now's the time for current shareholders to be afraid, however - expect it when you least expect it.

Top 5 Building Product Companies To Invest In 2014

On March 4, Mario Gabelli (Trades, Portfolio), the chairman and chief executive officer of GAMCO Investors Inc. added Griffon Corporation (GFF) at an average price of $12.61 and currently holds 6,752,733 shares of the stock, worth 0.01% of his portfolio.

So let's take a look at this company and try to explain to investors the reasons this is an apparently appealing investment opportunity in the building products industry, which is a cyclical one and driven by the overall health of the U.S. economy.

Positive Outlook

The company is a diversified manufacturer of building products, electronic information and communication systems, and specialty plastic films. It has three segments: Home and Building Products; which manufactures and markets residential, commercial and industrial garage doors through Clopay Building Products, and provides non-powered landscaping products through Ames True Temper Inc.

Top 5 Biotech Stocks To Watch Right Now: Steelcase Inc.(SCS)

Steelcase Inc. designs, manufactures, and distributes furniture systems and seating products, user-centered technologies, and interior architectural products primarily in North America, Europe, and Asia. Its furniture systems portfolio consists of panel-based and freestanding furniture systems; and complementary products, such as storage, tables, and ergonomic worktools. The company also provides seating products, including ergonomic chairs; seating for collaborative or casual settings; and specialty seating for specific markets comprising healthcare and education. In addition, its interior architectural products include full and partial height walls and doors. Further, the company offers workplace strategy consulting, lease origination, and furniture and asset management services. Additionally, it designs, manufactures, and sells visual communication products, such as static and interactive electronic whiteboards to primary and secondary education markets, as well as manu factures and sells steel and ceramic surfaces to third-party fabricators for use in the manufacture of static whiteboards. It also designs and sells surface materials comprising textiles, wall coverings, shades, screens, and surface imagings primarily to architects and designers for use in business, residential, healthcare, and hospitality applications. It sells its products to corporate, government, healthcare, education, and retail customers through the Steelcase, Turnstone, Details, and Nurture brands; and Coalesse and Designtex brands. The company markets its products and services through a network of independent and company-owned dealers, as well as directly to end-use customers. The company was founded in 1912 and is headquartered in Grand Rapids, Michigan.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Shares of Steelcase (NYSE: SCS) got a boost, shooting up 12.21 percent to $16.36 after the company reported better-than-expected fourth-quarter earnings. Steelcase reported its Q4 earnings of $0.18 per share, beating analysts' estimates by $0.01 per share. Raymond James upgraded the stock from Outperform to Strong Buy and lifted the price target from $17.50 to $19.00.

• [By Jake L'Ecuyer]

  Shares of Steelcase (NYSE: SCS) got a boost, shooting up 11.21 percent to $16.36 after the company reported better-than-expected fourth-quarter earnings. Steelcase reported its Q4 earnings of $0.18 per share, beating analysts' estimates by $0.01 per share. Raymond James upgraded the stock from Outperform to Strong Buy and lifted the price target from $17.50 to $19.00.

• [By John Kell var popups = dojo.query(".socialByline .popC"); popups.forEach(func]

  Steelcase Inc.(SCS) swung to a fiscal fourth-quarter profit amid growth in the company’s Americas business. The year-earlier period included big asset write-downs and restructuring-related charges. Shares climbed 9.5% to $15.96 premarket.

• [By WWW.DAILYFINANCE.COM]

  Seth Wenig/APCEO Nick Woodman holds a GoPro camera in his mouth as he celebrates his GoPro's IPO. There were plenty of winners and losers this week, as the leading premium coffeehouse chain expanded its carbonated beverage offerings, and a disruptive video-streaming service got disrupted itself. Here's a rundown of the week's best and worst. GoPro (GPRO) -- Winner The initial public offering market got some fresh meat on Thursday when GoPro went public. The company behind the popular namesake cameras that extreme sports enthusiast like to wear was a hit. It priced at $24 a share -- at the high end of its initial range -- and that still wasn't enough. The stock opened at $28.65, closing out its first day of trading with a 31 percent gain. GoPro's growth has been stellar. Sales soared 87 percent last year to nearly hit $1 billion. However, there was a surprising decline in revenue during this year's first quarter. New GoPro investors are assuming that the most recent quarter's dip was a fluke. If it isn't a fluke, they can record their stumble in glorious high-def. Aereo -- Loser Sometimes it's the disruptor that gets disrupted. Aereo, the start-up service that offers local TV channels as a streaming platform, was pummeled by the U.S. Supreme Court. In a 6-3 decision, the court ruled that Aereo violated the copyrights of major TV networks by streaming their content without paying transmission fees. The move isn't the end for Aereo, but its prognosis has clearly deteriorated. Aereo thought that incorporating tiny remote antennas that subscribers can access online was similar enough to actual HD antenna ownership by individuals that its business model would be found to be legal. That didn't pan out, and consumers are unlikely to get a break this way from their ever-increasing cable and satellite TV bills. Starbucks (SBUX) -- Winner If you need to cool down in the Sun Belt, Starbucks has a few fizzy options. The java giant this week introduced its Fizzio lin

Top 5 Building Product Companies To Invest In 2014: GT Advanced Technologies Inc (GTAT)

GT Advanced Technologies Inc., incorporated on September 27, 2006, is diversified technology company with crystal growth equipment and solutions for the global solar, light emitting diode (LED) and electronics industries. The Company operates in three segments: its polysilicon business, its photovoltaic (PV), business and its sapphire business. The Company's principal products are Silicon Deposition Reactors (SDR) and related equipment used to produce polysilicon, the key raw material used in silicon-based solar wafers and cells; Advanced sapphire crystallization furnaces (ASF) which are used to crystallize sapphire boules, and Directional solidification (DSS) furnaces and related equipment used to cast multicrystalline and MonoCast crystalline silicon ingots. On January 7, 2013, the Company announced the idling of its HiCz pilot manufacturing facility in Hazelwood, Missouri. On November 8, 2012, the Company acquired certain assets of Twin Creeks Technologies, Inc. (Twin Creeks). In May 2013, the Company acquired the business of Thermal Technology LLC.

PV Business

The focus of the Company's PV business is the development, manufacture and sales of crystallization growth furnaces to produce silicon ingots used in the production of solar wafers. The Company's principal product line has been the DSS family of casting furnaces that are used to produce multicrystalline ingots and MonoCast ingots. As of December 31, 2012, the Company shipped approximately 3,300 DSS crystallization furnaces. The ingots are used to make photovoltaic (PV) solar wafers and cells. HiCz, or continuous Czochralski (Cz) growth process, produces monocrystalline ingots that are designed to produce more efficient wafers. The Company�� DSS furnace is a specialized furnace used to melt polysilicon and cast multicrystalline ingots. Multicrystalline ingots are used to produce solar wafers, which ultimately become solar cells. The Company markets its DSS crystallization furnaces under the names DSS450HP and DSS6! 50. The Company's largest capacity DSS furnace, the DSS650, is capable of producing ingots that weigh up to 650 kilograms using standard silicon feedstock. In January 2012, the Company introduced its MonoCast silicon casting technology that uses the DSS furnace architecture to produce ingots comprised of a high percentage of monocrystalline material. The Company is markets MonoCast technology under the name DSS450 MonoCast.

The Company�� ancillary equipment provides operators with material handling assistance during the preparation of the crucible before it is loaded with silicon and during the loading and unloading of the crucible into the DSS furnace chamber at the start of the growth process and out of the DSS furnace chamber at the conclusion of the ingot growth process. The Company's ancillary equipment includes crucible coating stations, crucible manipulators, loaders/unloaders, extraction tools and other material handling systems required to safely transport material during the ingot growth process. The Company sells replacement parts and consumables used in its DSS furnaces and other PV equipment.

Polysilicon Business

The Company's polysilicon business offers Silicon Deposition Reactors, which utilize the chemical vapor deposition process, and related trichlorosilane (TCS) technology and equipment along with engineering services to existing polysilicon producers and new market entrants. The Company's polysilicon business focuses on product design, quality control, engineering services, project management and process development related to the production of polysilicon. It markets its SDR reactors under the names SDR300, SDR400, SDR 500 and SDR 600. The Company provides equipment, technology and engineering services for the production and purification of TCSand silane. This hydrochlorination technology eliminates the need for silicon tetrachloride converters which are required when using certain other polysilicon production technology. The Company also pr! ovides an! cillary equipment and technologies for producing seed rods used in its SDR reactors and for handling and processing the polysilicon rods into a finished product.

Sapphire Business

The Company's sapphire business markets and sells of the Company's ASF systems to customers to enable them to produce sapphire material. The Company also produces sapphire material, on a limited basis, for the LED and other specialty markets at its sapphire pilot production facility in Massachusetts. Its ASF systems produce monocrystalline sapphire material, referred to as sapphire boules. The sapphire boules are used to make sapphire wafers, a substrate for manufacturing LEDs, as well as sapphire blanks and windows for such applications as medical devices and watch crystals. The Company's ASF technology is based on the heat exchanger method (HEM), which is a directional solidification technique, which crystallizes the sapphire meltstock material during the growth process. The Company also uses the facility as a research and development (R&D) center to test new technology developments prior to commercial release. The Company markets and sells its ASF systems under the name ASF100. The Company also provides engineering and product design, quality control, process engineering, engineering services and field services related to the operation of its ASF furnaces. The Company produces sapphire material on a limited basis at its pilot production facility in Massachusetts. The Company sells this material to customers in the LED and other markets, such as the aerospace, defenses and medical device.

The Company manufactures and sells two principal types of sapphire materials: hems Sapphire Material and Titanium-doped Sapphire (Ti:Sapphire) Material. Using the material derives from the sapphire boule generated with its ASF furnaces, the Company cut the sapphire material in a number of different dimensions and crystal orientations, in form factors such as cores, rods, blanks, windows and tubes. The! Company ! generates sapphire boules that are doped with titanium. The Company provides certain finishing and polishing for its Ti:Sapphire material.

The Company competes with ALD Vacuum Technologies AG, JYT Corporation, Ferrotec Corporation, PVA TePla AG, Centrotherm Elektrische Anlagen GmbH & Co., Jing Gong Technology, Zhejiang Jingsheng Mechanical & Electrical Co., Ltd, MSA Apparatus Construction for Chemical Equipment Ltd, Centrotherm Elektrische Anlagen GmbH & Co., Morimatsu Industry Co. Ltd., Poly Plant Project, Inc., Hemlock Semiconductor Corporation, Wacker Chemie AG, MEMC Electronic Materials, Inc., Renewable Energy Corporation ASA, Thermal Technology LLC, Advanced Renewable Energy Company, LLC, Rubicon Technology, Inc., Sapphire Technology Co. Ltd. (Korea), Kyocera International Inc., Saint-Gobain, Gavish Inc., and Monocrystal.

Advisors' Opinion:

• [By Garrett Cook]

  Shares of GT Advanced Technologies (NASDAQ: GTAT) were down 12.89 percent to $17.03 after UBS downgraded the stock from Buy to Hold.

  Peabody Energy (NYSE: BTU) shares tumbled 3.55 percent to $16.02 after Deutsche Bank downgraded the stock from Buy to Hold and lowered the price target from $23.00 to $19.00.

• [By Travis Hoium]

  It's been a long road for GT Advanced Technologies (NASDAQ: GTAT  ) and there are a lot of questions the company faces going forward. When will its technology take off? When will revenue pick up? And when can investors expect to see a profit.

Top 5 Building Product Companies To Invest In 2014: Taubman Centers Inc (TCO)

Taubman Centers, Inc. (TCO), incorporated November 21, 1973, operates as a self-administered and self-managed real estate investment trust (REIT). The Taubman Realty Group Limited Partnership (TRG) is a subsidiary of TCO that owns direct or indirect interests in all of its real estate properties. The Company owns, leases, acquires, disposes of, develops, expands and manages regional and super-regional shopping centers and interests therein. As of December 31, 2012, the Company owned a portfolio of 24 urban and suburban shopping centers in 12 states. The consolidated Businesses consist of shopping centers and entities that are controlled by ownership or contractual agreements, The Taubman Company LLC (Manager), and Taubman Properties Asia LLC and its subsidiaries (Taubman Asia). In December 2012, it acquired additional 49.9% (100% in total) interest in International Plaza, located in Tampa, Florida. Also in December 2012, it acquired additional 25% (50% in total) interest in Waterside Shops. In January 2014, Taubman Centers Inc announced the completion of the sale of land owned by Taubman in Syosset, New York, and Taubman's interest in Arizona Mills to Simon Property Group.

The Company�� centers are located in metropolitan areas, including Charlotte, Dallas, Denver, Detroit, Los Angeles, Miami, Nashville, New York City, Orlando, Phoenix, San Francisco, Tampa, and Washington, D.C. The centers range in size between 236,000 and 1.6 million square feet of gross leasable area (GLA) and between 186,000 and 646,000 square feet of Mall GLA. Of the 24 centers, 18 are super-regional shopping centers. The Company�� centers have approximately 3,000 stores operated by their mall tenants under approximately 850 trade names. The centers have 65 anchors, operating under 14 trade names. The centers lease over 95% of leased Mall GLA to national chains, including subsidiaries or divisions of Forever 21 (Forever 21, For Love 21, XXI Forever, and others), The Gap (Gap, Gap Kids, Baby Gap, Banana Republic, ! Old Navy, and others), and Limited Brands (Bath & Body Works/White Barn Candle, Pink, Victoria's Secret, and others).

Advisors' Opinion:

• [By Rich Duprey]

  Shopping-mall operator�Taubman Centers� (NYSE: TCO  ) �announced yesterday�its second-quarter dividend of $0.50 per share, the same rate it paid last quarter after raising the payout 8%, from $0.4625 per share.

Top 5 Building Product Companies To Invest In 2014: China Natural Resources Inc.(CHNR)

China Natural Resources, Inc., through its subsidiaries, engages in the acquisition and exploitation of mining rights. The company involves in the exploration, extraction, processing, and sale of iron, zinc, and other nonferrous metals extracted or produced at mines primarily located in Anhui Province in the People?s Republic of China. It also involves in the exploration, acquisition, construction, development, and operation of coal mines located in Guizhou Province, the People?s Republic of China. The company is based in Central, Hong Kong.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Top decliners in the sector included Arch Coal (NYSE: ACI), off 5.3 percent, and China Natural Resources (NASDAQ: CHNR), down 3.9 percent.

  Top Headline